OT Staff Reports

The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.

In a question and answer session, four leading ophthalmologists share their experiences with crosslinking, offering pearls that can help peers incorporate the procedure into their practice.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

Scientists from globally renowned top medical institutions, including the Cleveland Clinic Cole Eye Institute, University Hospitals Eye Institute, and Akron Children’s Hospital Vision Center, will present their latest research findings on major blinding disorders including children’s vision issues, age-related macular degeneration, and glaucoma.

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.

According to the AAO and Verana Health, the partnership seeks to increase clinical trials access, accelerate recruitment, and advance ophthalmic research.

In an effort to educate the public on GA, Prevent Blindness has created a variety of resources for patients in English and Spanish.

Mount Sinai study is the first to identify that heart attack, stroke and heart failure are linked to a specific type of age-related macular degeneration.

By placing the chin on the chinrest, Nidek’s NT-1p automatically detects the position of the eyes and begins measurement without pressing any buttons.

Teprotumumab-trbw is the first and only medicine approved by the FDA for the treatment of thyroid eye disease.

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

According to a news release, Eyenuk will use the capital to expand its AI product platform with additional disease indications and advanced care coordination, and to accelerate the platform’s global commercialization and adoption.

Hear how ophthalmologists and optometrists in the United States are recognizing the importance of this year's awareness day.

According to the Glaucoma Research Foundation, the collaborative research program will explore some of the common characteristics of glaucoma, Alzheimer’s.

Leading U.S. eye care experts advance eye health focused digital platform designed to make eye care part of daily self-care routine.

According to a Vanderbilt University news release, the International Retinal Research Foundation has extended a $10 million gift to establish a center dedicated to retinal vision research at the Vanderbilt Eye Institute and a directorship to support a physician-scientist leader in the Department of Ophthalmology and Visual Sciences.

The hour-long issue teaches the viewing ophthalmologist the technique and many modifications of intrascleral haptic fixation, an innovative approach when the capsule has been damage or is absent.

Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient Inc.

Provectus will have an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center of the Bascom Palmer Eye Institute.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

According to Nicox SA, the patients made their final 3-month visit last week. Topline results of the trial are expected in November.

Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.

Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

Heru debuts dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up.

Medication is administered after LASIK and injectable prophylaxis during cataract surgery.

Sigma extends access to powerful no-code cloudscale data analytics for industry-compliant data cloud so healthcare professionals and researchers can find faster answers to critical questions.